United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

34-46mmhg) below knee open toe lymphoedema garment dtck3 (medi uk ltd -

European Union - English - EMA (European Medicines Agency)

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Ireland - English - HPRA (Health Products Regulatory Authority)

chugai pharma france - lenograstim - powder and solvent for solution for injection/infusion - 34 million international unit(s)/millilitre - colony stimulating factors; lenograstim

European Union - English - EMA (European Medicines Agency)

glaxo group ltd. - fondaparinux sodium - venous thrombosis; pulmonary embolism; myocardial infarction; angina, unstable - antithrombotic agents - 1.5 mg/0.3 ml and 2.5 mg/0.5 ml, solution for injection:, prevention of venous thromboembolic events (vte) in patients undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip replacement surgery., prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5.1)., prevention of venous thromboembolic events (vte) in medical patients who are judged to be at high risk for vte and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease., , 2.5 mg/0.5 ml, solution for injection:, treatment of unstable angina or non-st segment elevation myocardial infarction (ua/nstemi) in patients for whom urgent (< 120 mins) invasive management (pci) is not indicated (see sections 4.4 and 5.1)., treatment of st segment elevation myocardial infarction (stemi) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy., , 5 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml solution for injection:, treatment of acute deep vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.,

Ireland - English - HPRA (Health Products Regulatory Authority)

chugai pharma uk ltd - lenograstim - pdr+solv for soln for inf/inj - 34 million iu/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

covidien nz ltd - ioversol 34% (provides 16% (160mg/ml) organically bound iodine) - solution for injection - 34 % - active: ioversol 34% (provides 16% (160mg/ml) organically bound iodine) excipient: sodium calcium edetate trometamol

New Zealand - English - Medsafe (Medicines Safety Authority)

covidien nz ltd - ioversol 34% (provides 16% (160mg/ml) organically bound iodine) - solution for injection - 34 % - active: ioversol 34% (provides 16% (160mg/ml) organically bound iodine) excipient: sodium calcium edetate trometamol

Ireland - English - HPRA (Health Products Regulatory Authority)

chugai pharma uk ltd - lenograstim - pdr+solv for soln for inf/inj - 34 million iu/ml

Canada - English - Health Canada

armitage carroll, division of langford inc. - piperazine - liquid - 34% - piperazine 34% - horses; poultry; swine (pigs)

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - desflurane (unii: crs35bz94q) (desflurane - unii:crs35bz94q) - desflurane 240 ml in 240 ml - suprane is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults. suprane is contraindicated as an inhalation agent for the induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events. suprane is indicated as an inhalation agent for maintenance of anesthesia for inpatient and outpatient surgery in adults and in pediatric patients. after induction of anesthesia with agents other than suprane, and tracheal intubation, suprane is indicated for maintenance of anesthesia in infants and children. suprane is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including coughing, laryngospasm, and secretions [see warnings and precautions (5.3) and clinical studies (14.5) ]. the use of suprane is contraindicated in the following conditions: risk summary there are no adequate and well-controlled studies in pregnant women